

GAU 1648 \$

PATENT
Attorney Docket No. ONV-044.01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Ningning Miao

Serial No.: 08/900,220

Filing Date: July 24, 1997

For: *Method of Treating Dopaminergic and
GABA-nergic Disorders*



Art Unit: 1648

Examiner: T. Wessendorf

#10
chr
1-27-99

CERTIFICATE OF MAILING

I hereby certify that the foregoing document is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, DC 20231 on this 28 day of December, 1998

Ariel Collazo

**RESPONSE TO RESTRICTION REQUIREMENT AND SEQUENCE LISTING
CORRECTION**

Box Amendment
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

RECEIVED
JAN 19 1999
MATRIX-CUSTOMER
SERVICE CENTER

In response to the Restriction Requirement, which was mailed from the U.S. Patent and Trademark Office on September 25 1998, in the above-identified patent application, Applicants provisionally elect with traverse, Group I, drawn to a method and preparation, classified in class 536, subclass 23.1.

The Examiner further requested that the Applicants elect a species as set forth on page 5 of the Office Action. However, the species provided by the Examiner do not include those set forth in claim 8, namely *pct* therapeutics which are small organic molecules. Applicants respectfully request that the Examiner allow them to provisionally elect this species. Claims 1-

Applicants: Ningning Miao et al.
Serial No.: 08/900,220
Filed: July 24, 1997
Doc. No.: 332005.1

12, 16 and 22-27 are readable thereon. The undersigned attempted to contact, and left a voice mail message with, the Examiner on December 24th and 27th regarding the Restriction Requirement but could not reach the Examiner, undoubtedly due to the holiday season. Applicants respectfully request that the Examiner contact the undersigned to discuss this election if it is not acceptable to her.

Applicants traverse this Restriction Requirement on the grounds that search of the claims of one group would necessarily include a search of the claims of the remaining groups; therefore, examination of all claims would not place an undue burden on the Examiner.

In response to the cited error in the length of the sequence listing, Applicants submit that they filed a corrected sequence listing on August 20, 1998, which corrected a missing A residue at the end of SEQ ID NO:8, thereby making the sequence listing 1191 nucleotides in length. Though Applicants received the postcard from the PTO indicating receipt of the corrected sequence listing, the present Restriction Requirement contained the original sequence listing, which was missing the A residue. Applicants respectfully submit that the sequence listing has already been corrected, thereby obviating the objection.

RECEIVED

JAN 19 1999

**MAINTENANCE CUSTOMER
SERVICE CENTER**